SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2012. Key financial results include: Total revenues of $47.2 million grew 77% compared with $26.6 million for the second quarter of 2011
